{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:47Z","timestamp":1740106907947,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Indolent lymphoma, including chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and follicular lymphoma (FL), can undergo histological transformation into an aggressive subtype, typically diffuse large B-cell lymphoma (DLBCL). The prognosis of transformed lymphoma is poor. In this study, we reported the efficacy and toxicity of a combination of venetoclax, dose-adjusted rituximab or obinutuzumab, etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide (VR-DA-EPOCH or VG-DA-EPOCH) in 11 patients with biopsy-proven histology transformation into DLBCL, including 8 patients with RT and 3 with transformed FL (tFL). The study was conducted between October 2019 and March 2023 at our single center. The median age of participants at enrolment was 53 years. Six patients (85.7%, 6\/7) achieved complete remission (CR) at the end of treatment. The best overall response rate (ORR) and CR rate were both 72.7%, respectively. Two patients received autologous hemopoietic stem cell transplant (ASCT) while two patients received ASCT concurrently with CAR-T therapy for consolidation. With a median follow-up of 13.5 (range, 2.4\u201329.8) months after enrollment, the median event-free survival, progression-free survival, and overall survival were 9.4, 11.5, and 17.5 months, respectively. Hematologic toxicities of grade \u22653 consisted of neutropenia (90.9%, 10\/11), thrombocytopenia (63.6%, 7\/11), and febrile neutropenia (54.5%, 6\/11). In conclusion, VR-DA-EPOCH or VG-DA-EPOCH was a promising strategy to achieve an early remission, bridging to cellular therapy within this population.<\/jats:p>","DOI":"10.1007\/s00277-024-05618-x","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T04:37:36Z","timestamp":1705898256000},"page":"1635-1642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience"],"prefix":"10.1007","volume":"103","author":[{"given":"Shuchao","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luomengjia","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeqin","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonglu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanbing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-6345","authenticated-orcid":false,"given":"Huayuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"issue":"8","key":"5618_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s11912-022-01274-4","volume":"24","author":"AM Sigmund","year":"2022","unstructured":"Sigmund AM, Kittai AS (2022) Richter's transformation. Curr Oncol Rep 24(8):1081\u20131090","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"5618_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","volume":"17","author":"AD Zelenetz","year":"2019","unstructured":"Zelenetz AD, Gordon LI, Abramson JS et al (2019) NCCN Guidelines insights: B-cell lymphomas, Version 3.2019. J Natl Compr Cancer Netw 17(6):650\u2013661","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3","key":"5618_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2019.224121","volume":"105","author":"Y Wang","year":"2020","unstructured":"Wang Y, Tschautscher MA, Rabe KG et al (2020) Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 105(3):765\u2013773","journal-title":"Haematologica."},{"issue":"1","key":"5618_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","volume":"35","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Robrecht S, Bahlo J et al (2021) Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 35(1):169\u2013176","journal-title":"Leukemia."},{"issue":"10","key":"5618_CR5","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","volume":"100","author":"R Elnair","year":"2021","unstructured":"Elnair R, Ellithi M, Kallam A, Shostrom V, Bociek RG (2021) Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database. Ann Hematol 100(10):2513\u20132519","journal-title":"Ann Hematol"},{"issue":"1","key":"5618_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","volume":"125","author":"C Casulo","year":"2015","unstructured":"Casulo C, Burack WR, Friedberg JW (2015) Transformed follicular non-Hodgkin lymphoma. Blood. 125(1):40\u201347","journal-title":"Blood."},{"issue":"15","key":"5618_CR7","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","volume":"24","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM, O'Brien S, Khouri I et al (2006) Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24(15):2343\u20132351","journal-title":"J Clin Oncol"},{"issue":"26","key":"5618_CR8","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS et al (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31(26):3272\u20133278","journal-title":"J Clin Oncol"},{"issue":"12","key":"5618_CR9","doi-asserted-by":"publisher","first-page":"E239","DOI":"10.1002\/ajh.23841","volume":"89","author":"P Langerbeins","year":"2014","unstructured":"Langerbeins P, Busch R, Anheier N et al (2014) Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol 89(12):E239\u2013E243","journal-title":"Am J Hematol"},{"issue":"2","key":"5618_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.15035","volume":"180","author":"KA Rogers","year":"2018","unstructured":"Rogers KA, Huang Y, Ruppert AS et al (2018) A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol 180(2):259\u2013266","journal-title":"Br J Haematol"},{"issue":"8","key":"5618_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF et al (2017) Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 35(8):826\u2013833","journal-title":"J Clin Oncol"},{"key":"5618_CR12","doi-asserted-by":"crossref","unstructured":"Davids MS, Rogers KA, Tyekucheva S et al (2022) Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood 139(5):686\u2013689","DOI":"10.1182\/blood.2021011386"},{"issue":"11","key":"5618_CR13","doi-asserted-by":"publisher","first-page":"e818","DOI":"10.1016\/S2352-3026(21)00273-8","volume":"8","author":"SC Rutherford","year":"2021","unstructured":"Rutherford SC, Abramson JS, Bartlett NL et al (2021) Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet Haematol 8(11):e818\u2013e827","journal-title":"Lancet Haematol"},{"issue":"8","key":"5618_CR14","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","volume":"99","author":"WH Wilson","year":"2002","unstructured":"Wilson WH, Grossbard ML, Pittaluga S et al (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 99(8):2685\u20132693","journal-title":"Blood."},{"issue":"27","key":"5618_CR15","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"1","key":"5618_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1182\/hematology.2022000345","volume":"2022","author":"PA Thompson","year":"2022","unstructured":"Thompson PA, Siddiqi T (2022) Treatment of Richter\u2019s syndrome. Hematology Am Soc Hematol Educ Program 2022(1):329\u2013336","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"5618_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","volume":"126","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND, Link BK, Byrtek M et al (2015) Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 126(7):851\u2013857","journal-title":"Blood."},{"issue":"22","key":"5618_CR18","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","volume":"34","author":"C Sarkozy","year":"2016","unstructured":"Sarkozy C, Trneny M, Xerri L et al (2016) Risk Factors and outcomes for patients with follicular lymphoma who had histologic transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. J Clin Oncol 34(22):2575\u20132582","journal-title":"J Clin Oncol"},{"issue":"5","key":"5618_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjh.14831","volume":"178","author":"S Alonso-Alvarez","year":"2017","unstructured":"Alonso-Alvarez S, Magnano L, Alcoceba M et al (2017) Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol 178(5):699\u2013708","journal-title":"Br J Haematol"},{"key":"5618_CR20","doi-asserted-by":"publisher","first-page":"100824","DOI":"10.1016\/j.blre.2021.100824","volume":"49","author":"A Petrackova","year":"2021","unstructured":"Petrackova A, Turcsanyi P, Papajik T, Kriegova E (2021) Revisiting Richter transformation in the era of novel CLL agents. Blood Rev 49:100824","journal-title":"Blood Rev"},{"issue":"13","key":"5618_CR21","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","volume":"15","author":"D Rossi","year":"2009","unstructured":"Rossi D, Spina V, Cerri M et al (2009) Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res 15(13):4415\u20134422","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5618_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood.2020005734","volume":"137","author":"V Kohlhaas","year":"2021","unstructured":"Kohlhaas V, Blakemore SJ, Al-Maarri M et al (2021) Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Blood. 137(5):646\u2013660","journal-title":"Blood."},{"issue":"11","key":"5618_CR23","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1084\/jem.20131448","volume":"210","author":"G Fabbri","year":"2013","unstructured":"Fabbri G, Khiabanian H, Holmes AB et al (2013) Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 210(11):2273\u20132288","journal-title":"J Exp Med"},{"issue":"1","key":"5618_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","volume":"6","author":"L Pasqualucci","year":"2014","unstructured":"Pasqualucci L, Khiabanian H, Fangazio M et al (2014) Genetics of follicular lymphoma transformation. Cell Rep 6(1):130\u2013140","journal-title":"Cell Rep"},{"issue":"12","key":"5618_CR25","doi-asserted-by":"publisher","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","volume":"13","author":"R Kridel","year":"2016","unstructured":"Kridel R, Chan FC, Mottok A et al (2016) Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLoS Med 13(12):e1002197","journal-title":"PLoS Med"},{"issue":"20","key":"5618_CR26","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1182\/blood.2020005650","volume":"137","author":"J Klintman","year":"2021","unstructured":"Klintman J, Appleby N, Stamatopoulos B et al (2021) Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. Blood. 137(20):2800\u20132816","journal-title":"Blood."},{"issue":"11","key":"5618_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","volume":"133","author":"P Baliakas","year":"2019","unstructured":"Baliakas P, Jeromin S, Iskas M et al (2019) Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 133(11):1205\u20131216","journal-title":"Blood."},{"issue":"3","key":"5618_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/10428190109064589","volume":"42","author":"BS Dabaja","year":"2001","unstructured":"Dabaja BS, O'Brien SM, Kantarjian HM et al (2001) Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma 42(3):329\u2013337","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"5618_CR29","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/cncr.11238","volume":"97","author":"AM Tsimberidou","year":"2003","unstructured":"Tsimberidou AM, Kantarjian HM, Cortes J et al (2003) Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 97(7):1711\u20131720","journal-title":"Cancer."},{"issue":"2","key":"5618_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","volume":"26","author":"AM Tsimberidou","year":"2008","unstructured":"Tsimberidou AM, Wierda WG, Plunkett W et al (2008) Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter\u2019s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196\u2013203","journal-title":"J Clin Oncol"},{"issue":"5","key":"5618_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","volume":"13","author":"AM Tsimberidou","year":"2013","unstructured":"Tsimberidou AM, Wierda WG, Wen S et al (2013) Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 13(5):568\u2013574","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"5618_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/ejh.12474","volume":"95","author":"E Durot","year":"2015","unstructured":"Durot E, Michallet AS, Lepretre S, Le QH, Leblond V, Delmer A (2015) Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study. Eur J Haematol 95(2):160\u2013167","journal-title":"Eur J Haematol"},{"issue":"1","key":"5618_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjh.14177","volume":"175","author":"TA Eyre","year":"2016","unstructured":"Eyre TA, Clifford R, Bloor A et al (2016) NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. Br J Haematol 175(1):43\u201354","journal-title":"Br J Haematol"},{"issue":"16","key":"5618_CR34","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1182\/blood.2019000858","volume":"134","author":"Y Wang","year":"2019","unstructured":"Wang Y, Link BK, Witzig TE et al (2019) Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood. 134(16):1289\u20131297","journal-title":"Blood."},{"issue":"4","key":"5618_CR35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1365-2141.2011.08781.x","volume":"154","author":"MS Czuczman","year":"2011","unstructured":"Czuczman MS, Vose JM, Witzig TE et al (2011) The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol 154(4):477\u2013481","journal-title":"Br J Haematol"},{"issue":"10","key":"5618_CR36","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","volume":"125","author":"M Tsang","year":"2015","unstructured":"Tsang M, Shanafelt TD, Call TG et al (2015) The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 125(10):1676\u20131678","journal-title":"Blood."},{"issue":"1","key":"5618_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bjh.15440","volume":"185","author":"A Visentin","year":"2019","unstructured":"Visentin A, Imbergamo S, Scomazzon E et al (2019) BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. Br J Haematol 185(1):193\u2013197","journal-title":"Br J Haematol"},{"issue":"12","key":"5618_CR38","doi-asserted-by":"publisher","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","volume":"8","author":"TA Eyre","year":"2021","unstructured":"Eyre TA, Schuh A, Wierda WG et al (2021) Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. Lancet Haematol 8(12):e912\u2013e921","journal-title":"Lancet Haematol"},{"issue":"10277","key":"5618_CR39","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W et al (2021) Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 397(10277):892\u2013901","journal-title":"Lancet."},{"issue":"5","key":"5618_CR40","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Feugier P, Flinn IW et al (2021) A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 137(5):600\u2013609","journal-title":"Blood."},{"issue":"18","key":"5618_CR41","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","volume":"5","author":"AF Herrera","year":"2021","unstructured":"Herrera AF, Ahn KW, Litovich C et al (2021) Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv 5(18):3528\u20133539","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"5618_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-138904","volume":"136","author":"O Benjamini","year":"2020","unstructured":"Benjamini O, Shimoni A, Besser M et al (2020) Safety and efficacy of CD19-CAR T cells in Richter\u2019s transformation after targeted therapy for Chronic lymphocytic leukemia. Blood. 136(Supplement 1):40\u201340","journal-title":"Blood."},{"issue":"27","key":"5618_CR43","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L et al (2020) Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol 38(27):3119\u20133128","journal-title":"J Clin Oncol"},{"issue":"11","key":"5618_CR44","doi-asserted-by":"publisher","first-page":"910.e1","DOI":"10.1016\/j.jtct.2021.08.012","volume":"27","author":"Y Cao","year":"2021","unstructured":"Cao Y, Xiao Y, Wang N et al (2021) CD19\/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed\/refractory aggressive B cell lymphomas. Transplant Cell Ther 27(11):910.e1\u2013910.e11","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"5618_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bjh.17815","volume":"196","author":"G Bastidas-Mora","year":"2022","unstructured":"Bastidas-Mora G, Bea S, Navarro A et al (2022) Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. Br J Haematol 196(1):146\u2013155","journal-title":"Br J Haematol"},{"issue":"4","key":"5618_CR46","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3324\/haematol.2021.278304","volume":"107","author":"A Visentin","year":"2022","unstructured":"Visentin A, Bonaldi L, Rigolin GM et al (2022) The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica. 107(4):868\u2013876","journal-title":"Haematologica."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05618-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05618-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05618-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:04:00Z","timestamp":1712901840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05618-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["5618"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05618-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"20 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the Institutional Research Board of The First Affiliated Hospital of Nanjing Medical University. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent of publication was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}